Pancreatic cancer is an almost uniformly fatal disease that will strike -33,000 families in the United States this year. It has been estimated that 5-10% of these cancers have a familial basis. A better understanding of the genetic basis for the familial aggregation of pancreatic cancer will form a foundation for counseling patients and their families, a basis for the rational application of new tests to detect this disease earlier, and may lead to gene-specific therapies. This project builds on progress made and collaborations established during the last funding period of this Gl SPORE in which we demonstrated: a) that individuals with a strong family history of pancreatic cancer have a significantly increased risk of developing pancreatic cancer, b) that these at-risk individuals can be screened by endoscopic ultrasound for early neoplasia, c) that this early neoplasia has a distinct phenotype, d) that germ-line mutations in BRCA2 and other members of the Fanconi anemia pathway are associated with an increased risk of developing pancreatic cancer, and e) that cancers with these mutations are selectively sensitive to gene-specific therapies. We now propose to: 1) define the patterns of clustering of pancreatic and non-pancreatic cancers in families and to use these data to develop a risk prediction tool (PancPRO) for clinical use, 2) perform a case-control genome wide association study on familial pancreatic cancer kindreds of Ashkenazi Jewish descent, and 3) determine the gene(s) responsible for the familial clustering of pancreatic cancer. The studies proposed here directly address a research priority identified in the NCI Pancreatic Cancer Program Review Group (PRG) - """"""""Identify genetic factors, environmental factors, and gene-environment interactions that contribute to pancreatic cancer development."""""""" The studies proposed will utilize tissues and families from the Cores (Core 2 and Core 3) to translate genetic discoveries made in Project 1B and 3C to patient care and they will provide a scientific basis for the selection of patients

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-17
Application #
8096763
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
17
Fiscal Year
2010
Total Cost
$178,713
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205

Showing the most recent 10 out of 883 publications